A phase II trial using AR antagonist bicalutamide in ER-/PR-/AR+ metastatic BC showed a 19% clinical benefit rate (CBR), providing a clinical proof-of-principle for targeting the AR in TNBC [261]. The gene discussed is ESR1; the disease is breast cancer.